2[1]Read R C, Morrissey I, Ambler J E, et al. Clinician's Manual on Respi-ratory Tract Infections and Fluoroquinolones[M]. London: Science Press Ltd,2000.29-51. 被引量：1
3[2]Drugeon H B, Juvin M E, Bryskier. Relative potential for selection of fluoroquinolone-resistant streptococcus pneumoniae strains by levofloxacin:comparison with ciprofloxacin, sparfloxacin and ofloxacin[J]. J Antimicrob Chemother, 1999, 43(Suppl): 55-59. 被引量：1
4[3]Sullivan J G, McElroy A, Honsinger R W. et al. A double-blind, rando-mized study of safety and efficacy treating community acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin[J]. J Respir Dis, 1999,20(Suppl):49-59. 被引量：1
5[4]Forgarty C, Dowell M E, Ellison W T, et al. A prospective, randomized, double-blind study treating community-acquired pneumonia in hospitalized patients:gatifloxacin VS ceftriaxone/clarithromycin[J]. J Respir Dis, 1999,20(Suppl):60-69. 被引量：1
6[5]Ball P, Wilson R, Mandell L, et al. Efficacy of gemifloxacin in acute exacerbations of chronic bronchitis:a randomized, double-blind comparison with trovafloxacin[J]. J Chemother, 2001,13(3):288-298. 被引量：1
7[6]File T M Jr, Schlemmer B, Garau J, et al. Efficacy and safety of gemi-floxacin in the treatment of community-acquired pneumonia:a randomized, double-blind comparison with trovafloxacin[J]. J Antimicrob Chemother, 2001, 48(1): 746-747. 被引量：1
8[7]Amer Thorac Society. Guidelines for the management of adults with com-munity-acquired pneumonia[J]. Am J Respir Crit Care Med, 2001,163(7):1730-1754. 被引量：1
9[8]Heffelfingers J D, Dowell S F, Jorgensen J H, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the drug-resistant streptococcus pneumoniae therapeutic working group[J]. Arch Intern Med, 2000, 160(10):1399-1408. 被引量：1
10[9]Tillotson G, Zhao X, Drilica K. Fluoroquinolones as pneumococcal ther-apy: Closing the barn door before the horse escapes[J]. Lancet Infect Dis, 2001,1(3):145-146. 被引量：1
